Company News

Company News
August 17, 2021
CORE ONE LABS ACQUIRES FRONTIER MYCOLOGY
Vancouver, British Columbia, Canada – August 17, 2021 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”)...
Read more
Company News
August 12, 2021
CORE ONE LABS’ CLINICS SUBMIT APPLICATION TO TREAT PATIENT WITH PSILOCYBIN PSYCHEDELIC- ASSISTED THERAPY
Vancouver, British Columbia, Canada – August 13, 2021 – Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (the “Company”) a research and technology company focused...
Read more
Company News
August 07, 2021
Core One Labs to Move Its Psychedelic Formulations for the Treatment of Stroke and Depression Toward Clinical Development
Vancouver, British Columbia, Canada – August 7, 2021 – Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”)...
Read more
Company News
August 04, 2021
Core One Labs’ Virtual Town Hall Reveals Company is Nearing Production of Biosynthesized Psilocybin: Breakthrough In the Psychedelic Space Expected Upon Successful Completion
Vancouver, British Columbia, Canada – August 4, 2021 – Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”)...
Read more
Company News
July 30, 2021
CORE ONE’S DR. ROBERT E.W. HANCOCK TO HOST VIRTUAL TOWNHALL WEBCAST AND PRESENT ON PROPRIETARY BIOSYNTHESIZED PSILOCYBIN WEDNESDAY, AUGUST 4, 2021
Vancouver, British Columbia, Canada – July 30, 2021 – Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”)...
Read more
Company News
July 26, 2021
CORE ONE LABS’ AKOME SEEKS TO REVOLUTIONIZE TREATMENT OF PARKINSON’S DISEASE AND SUBMITS APPLICATION TO PROTECT IP
Vancouver, British Columbia, Canada – July 26, 2021 – Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (the “Company”) is pleased to announce...
Read more